H.C. Wainwright has adjusted its price target for Kala Pharmaceuticals (KALA, Financial), lowering it from $15 to $12. Despite this reduction, the firm maintains a Buy rating on KALA's shares. This decision follows the company's recent third-quarter financial report, which likely influenced the reassessment of its stock value.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 2 analysts, the average target price for Kala Bio Inc (KALA, Financial) is $15.00 with a high estimate of $15.00 and a low estimate of $15.00. The average target implies an upside of 266.75% from the current price of $4.09. More detailed estimate data can be found on the Kala Bio Inc (KALA) Forecast page.
Based on the consensus recommendation from 2 brokerage firms, Kala Bio Inc's (KALA, Financial) average brokerage recommendation is currently 1.5, indicating "Buy" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
